an illuminated digest of the research
BPC-157 is a cytoprotective research peptide studied for tissue repair across two decades of preclinical work.
The mechanism is an angiogenesis story; the dose record is animal per-kilogram figures; the human evidence is three small pilots. This is a literature digest that reads each finding slowly and cites every number.
What BPC-157 is, in one careful paragraph
BPC-157 is a synthetic 15-amino-acid peptide — a pentadecapeptide — derived from a partial sequence of a protein found in human gastric juice. Its authors call it a "stable gastric pentadecapeptide," and across the literature it is framed as a cytoprotective compound: a molecule studied for its capacity to protect and repair tissue rather than to treat a named disease. The peptide carries the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, a molecular weight near 1419 Da, and the CAS number 137525-51-0. It is not a naturally circulating hormone, not a growth hormone, and not an approved drug anywhere. What it is, precisely, is the subject of an active and overwhelmingly preclinical research literature — and that literature, read against itself, is what this digest documents.
This site is editorial. It summarizes published research on BPC-157 and cites it. It is not a clinic, it does not provide medical advice, and it sells nothing. Where the evidence is strong it says so plainly; where the evidence stops — and for BPC-157 it stops early — it marks the gap rather than papering over it.
BPC-157 Peptide: Identity and Structure
The BPC-157 peptide is fifteen amino acids long, with the molecular formula C62H98N16O22 and a molecular weight of approximately 1419.53 Da [2]. The name "Body Protection Compound 157" reflects its origin as a fragment of a larger gastric-juice protein; it also appears in the literature under the development designations PL 14736, PLD-116, and PL-10. Suppliers commonly distribute it as the acetate salt.
The "stable gastric pentadecapeptide" label is not marketing — it is the descriptor its principal authors use, and it points to a genuine physical property: BPC-157 is reported to remain stable in human gastric juice, which is the basis of long-standing interest in oral and peroral administration [2]. That stability is the reason the peptide is studied at all by mouth; it is not, by itself, evidence that oral dosing works in people. The structure is settled; the route question is not.
BPC-157 Mechanism of Action
The best-characterized BPC-157 mechanism of action is pro-angiogenic and runs through the VEGFR2 receptor. In endothelial models the peptide up-regulates VEGFR2 expression and promotes its internalization, activating the downstream VEGFR2-Akt-eNOS (nitric-oxide) pathway; the effect raised vessel density in vivo and in vitro and accelerated blood-flow recovery in ischemic rat muscle, and it was blocked when endocytosis was inhibited [3]. Around that spine the literature adds the FAK-paxillin pathway (fibroblast outgrowth and migration), up-regulation of the growth-hormone receptor in tendon fibroblasts, and broad modulation of the nitric-oxide system [1].
Angiogenesis — the formation of new blood vessels from existing vasculature — is the through-line that ties the tendon, gut, and distant-organ findings together: tissue that repairs is tissue that has been re-vascularized. The mechanism is described carefully in the preclinical record and is the most reproducible claim in the file. It is also the source of the single most honest caveat on this site, because a molecule that drives new vessel growth raises long-term oncologic questions that the human data are nowhere near large enough to answer — a point the BPC-157 side effects section takes up directly.
What does BPC-157 do in the body?
In animal models BPC-157 is described as a cytoprotective peptide whose repair effects are most consistently linked to angiogenesis via VEGFR2-Akt-eNOS signaling [3]. It has accelerated healing of a fully transected rat Achilles tendon across biomechanical, functional, and microscopic measures [1], reduced gastric-ulcer area in rats [4], and been reported to protect distant organs such as liver, kidney, and lung from secondary damage [9]. These are findings in living systems other than human ones. The peptide's effect in the human body has been examined in only three small pilots, and none was an efficacy trial [5][6][7].
Read the BPC-157 mechanism of action section for the receptor-level detail, the BPC-157 cytoprotection page for the repair framework these effects sit inside, and the BPC-157 references for the full citation list.
Where the human evidence actually stands
Three small human pilots exist, and they are the entire human dataset. A 2025 first-in-human intravenous safety pilot infused BPC-157 in two healthy adults (10 mg on day one, 20 mg on day two, one-hour infusions) and reported no observed adverse events and no measurable changes in cardiac, hepatic, renal, thyroid, or glucose biomarkers — a reassuring result at a sample size of two [5]. A 2024 intravesical pilot in twelve interstitial-cystitis patients used a single 10 mg instillation and reported symptom resolution in most, with no adverse events, but it was uncontrolled [6]. An earlier intra-articular case series described reduced knee pain across several pain types, also uncontrolled [7].
A 2025 narrative review states the position without ornament: despite broad preclinical support, the human pilot studies are extremely limited, rigorous large-scale trials are lacking, and BPC-157 should be considered investigational and used with caution given its regulatory controversy and non-regulated availability [8]. That is the frame this site keeps. The animal record is large and consistent; the human record is three pilots and a handful of people. Both facts are true at once, and neither cancels the other. The pages that follow read each finding in turn — the mechanism, the dose record, the safety limits, and how compounded access stands today — and cite every number to its source.